Antibody Fc Engineering: Towards Better Therapeutics (Record no. 66429)

MARC details
000 -LEADER
fixed length control field 02521naaaa2200337uu 4500
001 - CONTROL NUMBER
control field https://directory.doabooks.org/handle/20.500.12854/40953
005 - DATE AND TIME OF LATEST TRANSACTION
control field 20220220045648.0
020 ## - INTERNATIONAL STANDARD BOOK NUMBER
International Standard Book Number 978-2-88945-678-9
020 ## - INTERNATIONAL STANDARD BOOK NUMBER
International Standard Book Number 9782889456789
024 7# - OTHER STANDARD IDENTIFIER
Standard number or code 10.3389/978-2-88945-678-9
Terms of availability doi
041 0# - LANGUAGE CODE
Language code of text/sound track or separate title English
042 ## - AUTHENTICATION CODE
Authentication code dc
100 1# - MAIN ENTRY--PERSONAL NAME
Personal name Rui Gong
Relationship auth
245 10 - TITLE STATEMENT
Title Antibody Fc Engineering: Towards Better Therapeutics
260 ## - PUBLICATION, DISTRIBUTION, ETC.
Name of publisher, distributor, etc. Frontiers Media SA
Date of publication, distribution, etc. 2018
300 ## - PHYSICAL DESCRIPTION
Extent 1 electronic resource (118 p.)
506 0# - RESTRICTIONS ON ACCESS NOTE
Terms governing access Open Access
Source of term star
Standardized terminology for access restriction Unrestricted online access
520 ## - SUMMARY, ETC.
Summary, etc. Monoclonal antibodies and Fc-fusion proteins used clinically are Fc-based therapeutics that grow fastest in the pharmaceutical industry. Since they both contain an Fc fragment, engineering of Fc fragments could be a platform for improving Fc-based drug efficacy. Fc engineering includes various aspects: stabilization of Fc; regulation of effector functions including antibody-dependent cell-mediated cytotoxicity, complement-dependent cytotoxicity; extension of serum half-life by modification of neonatal Fc receptor (FcRn) binding; monomerization or heterodimerization of Fc for design of new Fc formats. Currently, many new methods are being used in Fc engineering. Compared to traditional methods such as site mutagenesis on certain positions by amino acid replacement, new methods such as display-based technology can confer high throughput screening and obtain optimized variants relatively quickly, accelerating the drug development process. With the new methods, many new Fc variants were identified. On this Research Topic we are going to review the progress in current Fc engineering including the new engineering methods and the Fc variants or constructs they have produced, and the potential of these new Fcs in clinical use.
540 ## - TERMS GOVERNING USE AND REPRODUCTION NOTE
Terms governing use and reproduction Creative Commons
Use and reproduction rights https://creativecommons.org/licenses/by/4.0/
Source of term cc
-- https://creativecommons.org/licenses/by/4.0/
546 ## - LANGUAGE NOTE
Language note English
653 ## - INDEX TERM--UNCONTROLLED
Uncontrolled term effector function
653 ## - INDEX TERM--UNCONTROLLED
Uncontrolled term Fc receptor
653 ## - INDEX TERM--UNCONTROLLED
Uncontrolled term heterodimeric Fc
653 ## - INDEX TERM--UNCONTROLLED
Uncontrolled term Fc-fusion protein
653 ## - INDEX TERM--UNCONTROLLED
Uncontrolled term monomeric Fc
653 ## - INDEX TERM--UNCONTROLLED
Uncontrolled term Monoclonal antibody
653 ## - INDEX TERM--UNCONTROLLED
Uncontrolled term Fc engineering
700 1# - ADDED ENTRY--PERSONAL NAME
Personal name Tianlei Ying
Relationship auth
856 40 - ELECTRONIC LOCATION AND ACCESS
Host name www.oapen.org
Uniform Resource Identifier <a href="https://www.frontiersin.org/research-topics/4342/antibody-fc-engineering-towards-better-therapeutics">https://www.frontiersin.org/research-topics/4342/antibody-fc-engineering-towards-better-therapeutics</a>
Access status 0
Public note DOAB: download the publication
856 40 - ELECTRONIC LOCATION AND ACCESS
Host name www.oapen.org
Uniform Resource Identifier <a href="https://directory.doabooks.org/handle/20.500.12854/40953">https://directory.doabooks.org/handle/20.500.12854/40953</a>
Access status 0
Public note DOAB: description of the publication

No items available.